{"id":"NCT02449291","sponsor":"Acacia Pharma Ltd","briefTitle":"Study of APD421 as PONV Treatment (no Prior Prophylaxis)","officialTitle":"Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2015-05-20","resultsPosted":"2018-12-19","lastUpdate":"2019-01-22"},"enrollment":568,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Postoperative Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"APD421","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"APD421 standard","type":"EXPERIMENTAL"},{"label":"APD421 high","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV prophylaxis.","primaryOutcome":{"measure":"Complete Response (Success of Initial PONV Treatment)","timeFrame":"0-24 hours after treatment","effectByArm":[{"arm":"APD421 5mg IV","deltaMin":60,"sd":null},{"arm":"APD421 10mg IV","deltaMin":59,"sd":null},{"arm":"Placebo","deltaMin":39,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.016"},{"comp":"OG000 vs OG002","p":"0.016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":4,"countries":["United States","France","Germany"]},"refs":{"pmids":["31094774"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":191},"commonTop":["Flatulence","Nausea","Constipation","Infusion site pain"]}}